Article Text

Download PDFPDF
290 The impact of a national multidisciplinary tumor board for cancer during pregnancy
  1. J Heimovaara1,2,
  2. IA Boere3,
  3. J De Haan4,
  4. K Van Calsteren5,6,
  5. F Amant1,2,7,
  6. L Van Zuylen8 and
  7. C Lok2,7
  1. 1KU Leuven, Department of Oncology, Leuven, Belgium
  2. 2The Netherlands Cancer Institute (NKI) – Antoni van Leeuwenhoek, Department of Gynaecology, Amsterdam, Netherlands
  3. 3Erasmus MC Cancer Institute, Erasmus University Medical Center, Department of Medical Oncology, Rotterdam, Netherlands
  4. 4Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Department of Obstetrics and Gynaecology, Amsterdam, Netherlands
  5. 5University Hospital Leuven, Department of Obstetrics and Gynaecology, Leuven, Belgium
  6. 6KU Leuven, Department of Development and Regeneration, Leuven, Belgium
  7. 7Antoni van Leeuwenhoek, Center for Gynaecological Oncology Amsterdam (CGOA), Amsterdam, Netherlands
  8. 8Amsterdam University Medical Centers, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Department of Medical Oncology, Amsterdam, Netherlands


Introduction/Background*Physicians encounter pregnant women with cancer only incidentally, leading to lack of expertise or confidence to inform and treat these patients according to up to date guidelines and expert opinions. In the Netherlands, a national multidisciplinary tumor board (MDT) for cancer and pregnancy was founded in 2012, and consists of 33 physicians from all over the country. Requests to discuss patients in the MDT were received by e-mail and a recommendation letter was generated based on available literature and expert opinion of the board members.

Methodology All requests and recommendations were gathered in a database and analyzed for tumor type, stage, gestational age and recommendation given. A survey was sent out to 93 physicians who requested recommendations of the MDT, containing questions regarding the their experiences with the MDT and the impact on treatment decisions.

Result(s)*From December 2012 to May 2021, 209 recommendations were formulated, mostly regarding pregnant patients with breast cancer (n=65), cervical cancer (n=32), haematological malignancies (n= 32), rare cancer types (n=30) and melanoma (n=21). Questions were asked regarding possibilities of ionized imaging, chemotherapy, hormonal therapy or immunotherapy during pregnancy and possible effects on the child, the sequence of the different treatment components and questions on fertility. Response rate of the questionnaire was 54%. Overall satisfaction with the recommendations of the MDT was high, and 94% of the respondents informed their patients about consulting the MDT and felt supported by the received recommendations.

Conclusion*A national MDT for cancer and pregnancy is frequently consulted and highly appreciated by physicians. Next to that, it increases expertise of its members about this rare coincidence of cancer and pregnancy. We highly recommend to establish an (inter)national MDT in each country. Figure 1 shows the important steps necessary to establish an MDT for cancer in pregnancy based on our experience.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.